key: cord-0711790-qwqyg2g5
authors: Strauss, Alexandra T.; Hallett, Andrew M.; Boyarsky, Brian J.; Ou, Michael T.; Werbel, William A.; Avery, Robin K.; Tobian, Aaron A. R.; Massie, Allan B.; Hamilton, James P.A.; Garonzik‐Wang, Jacqueline M.; Segev, Dorry L.
title: Antibody response to SARS‐CoV‐2 messenger RNA vaccines in liver transplant recipients
date: 2021-08-18
journal: Liver Transpl
DOI: 10.1002/lt.26273
sha: 497efe98afa1c5f61a1727ce60223c822ff801fb
doc_id: 711790
cord_uid: qwqyg2g5

Prior studies have demonstrated a decreased humoral response in solid organ transplant recipients (SOTRs) to SARS‐CoV‐2 mRNA vaccination (17% antibody response after dose 1, 54% after dose 2) as compared to the general population (100%). However, these studies were dominated by kidney transplant recipients, and included only a small percentage of liver transplant (LT) recipients (19.6%).(1–4) Since LT recipients often receive milder induction and maintenance immunosuppression, they may have a more robust humoral response. To investigate this, we studied SARS‐CoV‐2 antibody development in a cohort of LT recipients who completed a two‐dose mRNA vaccine series of either mRNA‐1273 (Moderna) or BNT162b2 (Pfizer‐BioNTech).

This article is protected by copyright. All rights reserved Prior studies have demonstrated a decreased humoral response in solid organ transplant recipients (SOTRs) to SARS-CoV-2 mRNA vaccination (17% antibody response after dose 1, 54% after dose 2) as compared to the general population (100%). However, these studies were dominated by kidney transplant recipients, and included only a small percentage of liver transplant (LT) recipients (19.6%). (1) (2) (3) (4) Since LT recipients often receive milder induction and maintenance immunosuppression, they may have a more robust humoral response. To investigate this, we studied SARS-CoV-2 antibody development in a cohort of LT recipients who completed a two-dose mRNA vaccine series of either mRNA-1273 (Moderna) or BNT162b2 (Pfizer-BioNTech).

Inclusion criteria were post-liver transplant patients with no reported prior positive SARS-CoV-2 polymerase chain reaction result. Participants were excluded if <18 years old. Participants were recruited via convenience sampling through social media or transplant centers advertisements, completed a two-dose mRNA vaccine course between 1/7/2021 and 3/26/2021, and were followed through 4/7/2021. Demographics, body mass index (BMI), prior COVID-19 diagnosis and hospitalization, transplant info, medications, other immune conditions, and allergies were collected. The study had Institutional Review Board approval, and informed consent was obtained. The blood sampling protocol utilized two SARS-CoV-2 spike protein immunoassays (EUROIMMUN to the S1 domain and Roche Elecsys to the receptor binding domain [RBD] of the SARS-CoV-2 spike protein) and has been described elsewhere.(1) We have shown in prior work that the distribution of vaccine responses did not differ when using anti S1 or anti RBD assay.(4) Post-dose-1 (D1) assay was performed as close to dose-2 (D2) as possible, and post-D2 assay was collected as close to 28 days as possible.

Of note, the Roche assay is artificially truncated at >250.

Participants were divided into three categories: "priming dose responders" (developed antibodies after both D1 and D2), "booster responders" (antibodies only after D2), and "non-responders" (no antibodies after both doses). The proportion of patients who developed a positive antibody response was assessed with exact binomial 95% Cis, and associations between variables were assessed using modified Poisson regression with a robust variance estimator. All 2-sided and α-level 0.05 testing was performed using Stata16.0/IC (College Station, TX).

Of 225 participants meeting inclusion criteria, 201 provided blood specimens post-D1. Of these, 161 provided specimens after D2, and 26 of which were previously reported in an all-organ summary of antibody responses (4) . In the full cohort of 161 participants, 53% received BNT162b2 and 47% received mRNA-1273 vaccine (Table 1) . Antibody was detectable in 34% (95%CI, 27%-42%) of participants at a median of 21 days (IQR, 19-25 days) after D1, and in 81% (95%CI, 74%-87%) at a median of 30 days (IQR, 28-31 days) after D2 ( Figure 1 ); 34% were priming dose responders (D1+/D2+), 47% booster responders (D1-/D2+), and 19% non-responders ( Table 2 ). The median semi-quantitative SARS-CoV-anti-spike antibody immunoassay after D2 was >250 U/mL (IQR 250, 250) on Roche Elecsys testing for priming dose responders, 81.9 U/mL (IQR 12.4, 250) for booster responders, and 0 (IQR 0, 0) for non-responders. A similar trend was seen for those tested with EUROIMMUN immunoassays (Table 3) . Crossover between immunoassays was minimal (7/161). No participants reported a laboratory confirmed diagnosis of COVID-19 following vaccination by end of follow-up.

Of 66 LT recipients on an anti-metabolite, 18% were priming dose responders, 42% booster responders, and 39% non-responders ( Our findings of a robust immune response of 81% are in contrast to an Israeli cohort of 80 LT recipients who had received two doses of the BNT162b2 vaccine and demonstrated an antibody response of only 47.5%. (5) This difference may be due to a different assay or other population factors such as age or anti-metabolite use.

Our study augments these findings to a larger sample size and patients that received the mRNA-1273 vaccine as well.

Differences in antibody response between the mRNA vaccine types may be related to dosing, timing, or drug delivery formulations. The mRNA-1273 vaccine series is two 100mg doses separated by 28 days, and the

This article is protected by copyright. All rights reserved BNT162b2 vaccine series is two 30mg doses 21 days apart.(2) The greater antibody response to the higher dosed mRNA-1273 vaccine might suggest a dose-response relationship. Differences between the effects of different vaccine dosing may be less apparent in the general population because both are so highly immunogenic in immunocompetent people, but an immunocompromised population may "unmask" these potential differences.

Limitations include selection bias resulting from convenience sampling, which contributed to sociodemographic homogeneity. Since race has not been found to be associated with antibody response, the difference in target population representation likely does not largely affect external validity. There was no immunocompetent comparator group; this makes direct comparisons difficult, but the robust 100% response rate seen in the general population studies is a notable benchmark.(2) Future immunologic response investigations could include co-morbidities and immunosuppression doses and drug levels, which were not collected in our study, as well as outcomes of interest such as B-cell/T-cell responses, SARS-CoV-2 infection, hospitalizations, and mortality. We used two serological assays to assess antibody response, but this was to enable us to study as many liver transplant recipients as possible. As explained above (see Methods), there is very high correlation between anti-S1 and anti-RBD assays, so the use of two assays likely did not lead to substantial measurement error. Despite these limitations, this nationwide sample of patients during a rapidly evolving clinical climate provides the transplantation community and primary care providers with immunogenicity data using readily available commercial assays for this unique population.

In conclusion, LT recipients who received two doses of SARS-CoV-2 mRNA vaccines have a much more robust antibody response compared to other SOTRs. Those vaccinated within 6 years from transplant, on antimetabolite immunosuppression, or vaccinated with BNT162b2 are more likely to have a diminished response.

LT recipients may have different clinical factors contributing to a more robust response and important considerations for anti-metabolite treatment peri-vaccination. Therefore, guidelines should be tailored in this population. 

This article is protected by copyright. All rights reserved 

This article is protected by copyright. All rights reserved 

Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Safety of the First Dose of SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients

Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients

Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients

Accepted Article